Grail unveils competitive ASCO data from second substudy of CCGA trial
Just a day after the launch of the latest liquid biopsy company, data from Grail show it will be a tight race to develop a multicancer liquid biopsy test for early cancer detection -- and that Grail’s decision to focus on methylation signatures may be paying off.
Grail Inc. (Menlo Park, Calif.) announced data